Source : New York Times 3 May 2008
Pfizer has started settling cases over its Celebrex and Bextra painkillers. More than 3,000 patients have claimed that the drugs caused heart attacks and strokes.
Celebrex, which is in the same class of medicines as Merck’s recalled Vioxx, is Pfizer’s third-best-selling drug. The product is still on the market, and generated $2.3 billion in sales in 2007. Pfizer withdrew Bextra in April 2005 after it was tied to a potentially fatal skin condition.
Pfizer has already reached settlements with three law firms representing more than 200 of the thousands who sued over the drugs. Firms have been offered $40,000 to $50,000 a client to resolve Bextra cases, and as much as $200,000 a client for Celebrex.
No comments:
Post a Comment